Christopher D. M. Fletcher

From WikiMD's WELLNESSPEDIA

Christopher D. M. Fletcher is a renowned pathologist specializing in the study of soft tissue tumors. He is currently the Vice Chair for Anatomic Pathology at Brigham and Women's Hospital, and a Professor of Pathology at Harvard Medical School.

Early Life and Education[edit]

Fletcher was born and raised in the United Kingdom. He completed his medical education at the University of London, where he developed a keen interest in pathology.

Career[edit]

After completing his education, Fletcher moved to the United States and began his career at the Brigham and Women's Hospital in Boston, Massachusetts. He has made significant contributions to the field of soft tissue pathology, particularly in the diagnosis and classification of soft tissue tumors.

Fletcher has authored numerous scientific articles and textbooks, including the widely used reference book "Diagnostic Histopathology of Tumors". He is also the editor-in-chief of the International Journal of Surgical Pathology.

Research[edit]

Fletcher's research primarily focuses on the molecular genetics of soft tissue tumors. His work has led to the identification of several novel genetic alterations associated with these tumors, which has significantly improved their diagnosis and treatment.

Awards and Honors[edit]

Fletcher has received numerous awards and honors for his contributions to pathology, including the United States and Canadian Academy of Pathology (USCAP) Gold Medal, the highest honor awarded by the organization.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.